ArticleBreast cancer (Dove Medical Press)2022

Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States.

Yitian Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.